Patients with neurodegenerative disease are most vulnerable to COVID-19 infections and measures of social distancing and quarantine. It is unknown how COVID-19 infections and its long-term effects influence the development of neurodegenerative diseases. The COVID19 pandemic offers an opportunity to understand important aspects of neurodegenerative diseases.
7 december 2021
14 december 2021,
The aim of the call is to establish a number of innovative, multi-disciplinary European expert Working Groups to discuss research strategies that concern the impact of COVID-19 on the development and progression of neurodegenerative disease and on the care of patients with neurodegenerative diseases. These strategies can consider the impact of COVID-19 on neurodegenerative disease research itself, how it is conducted and how it influenced technological innovations for neurodegenerative diseases. Furthermore, they can explore methods and sources of data to enable or improve the surveillance of the impacts of COVID-19 as they relate to the development or progression of neurodegenerative diseases.
Working Groups must focus on one or several of the following neurodegenerative diseases: Alzheimer’s disease and other dementias, Parkinson’s disease and PD‐related disorders, Prion diseases, Motor neuron diseases, Huntington’s disease, Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA).
Working Groups are to be research community-led and must demonstrate a scientific benefit from international working. They should aim at pushing forward the conceptualization of such topics and envisage the provision of best-practice guidelines and methodological frameworks of value to the wider research community. Patient related research as envisaged by this call benefits from the active involvement of the persons concerned. Thus, Working Groups need to adequately involve patients, their relatives and carers and the public, in the planning stage during the application as well as in the later work developed by the postulating group. In the application it must be described how patients are involved and from where they are recruited. If such an approach is missing it must be well justified.
Only transnational Working Groups are funded. A minimum of six experts, including the coordinator, from at least three different countries must be involved in a Working Group, which should ideally not exceed 25 participants.
Each Working Group can bid up to 50.000 € (plus institutional overhead) for support of its activities, which should normally not exceed a time period of 9 months.
You may submit your joint proposal on behalf of the entire Working Group via the JPND electronic submission and evaluation system no later than 12:00h C.E.T. on December 14, 2021
The full call for expert working groups 2021 can be found on the European JPND website
Call for Expert Working Groups 2021: “The impact of COVID-19 on Neurodegenerative Diseases research”
ZonMw-programma Joint Programming Initiative Neurodegenerative Diseases (JPND)
European website JPND Research
Please contact us with any questions that are not covered in the FAQs. For general queries, please contact Abida Durani (JPND@zonmw.nl)